OBJECTIVE: To analyze the efficacy of treating postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone furoate nasal spray. DESIGN: Randomized trial. SETTING: Academic research. PATIENTS: Seventy-one patients who were diagnosed as having postviral olfactory loss. MAIN OUTCOME MEASURES: All patients underwent olfactory function tests, including the butanol threshold test (BTT) and the cross-cultural smell identification test (CCSIT), and follow-up tests were performed 4 weeks later. In the interim, 28 patients were treated withprednisolone for 2 weeks (monotherapy), and the other 43 patients were treated with prednisolone for 2 weeks plus G biloba for 4 weeks (combination therapy). All patients used mometasone nasal spray twice daily for 4 weeks. RESULTS: Scores on the BTT and CCSIT significantly increased after treatment in both groups (P < .001 for both). The mean (SD) BTT score changes were 1.4 (2.2) in the monotherapy group and 2.2 (2.9) in the combination therapy group (P = .22). The mean (SD) CCSIT score changes were 0.9 (1.7) in the monotherapy group and 1.9 (2.7) in the combination therapy group (P = .11). On the BTT, the treatment response (defined as a score increase of > or =3) rates were 32% (9 of 28) in the monotherapy group and 37% (16 of 43) in the combination therapy group (P = .66), and the odds ratio was 1.25 (95% confidence interval, 0.46-3.42). On the CCSIT, the treatment response rates were 14% (4 of 28) in the monotherapy group and 33% (14 of 43) in the combination therapy group (P = .08), and the odds ratio was 2.89 (95% confidence interval, 0.84-9.97). CONCLUSIONS:Olfactory function in patients withpostviral olfactory loss was significantly improved by both treatment modalities. Although the treatment response was not statistically different between the monotherapy group and the combination therapy group, the addition of G biloba showed a tendency of greater efficacy in the treatment of postviral olfactory loss.
RCT Entities:
OBJECTIVE: To analyze the efficacy of treating postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone furoate nasal spray. DESIGN: Randomized trial. SETTING: Academic research. PATIENTS: Seventy-one patients who were diagnosed as having postviral olfactory loss. MAIN OUTCOME MEASURES: All patients underwent olfactory function tests, including the butanol threshold test (BTT) and the cross-cultural smell identification test (CCSIT), and follow-up tests were performed 4 weeks later. In the interim, 28 patients were treated with prednisolone for 2 weeks (monotherapy), and the other 43 patients were treated with prednisolone for 2 weeks plus G biloba for 4 weeks (combination therapy). All patients used mometasone nasal spray twice daily for 4 weeks. RESULTS: Scores on the BTT and CCSIT significantly increased after treatment in both groups (P < .001 for both). The mean (SD) BTT score changes were 1.4 (2.2) in the monotherapy group and 2.2 (2.9) in the combination therapy group (P = .22). The mean (SD) CCSIT score changes were 0.9 (1.7) in the monotherapy group and 1.9 (2.7) in the combination therapy group (P = .11). On the BTT, the treatment response (defined as a score increase of > or =3) rates were 32% (9 of 28) in the monotherapy group and 37% (16 of 43) in the combination therapy group (P = .66), and the odds ratio was 1.25 (95% confidence interval, 0.46-3.42). On the CCSIT, the treatment response rates were 14% (4 of 28) in the monotherapy group and 33% (14 of 43) in the combination therapy group (P = .08), and the odds ratio was 2.89 (95% confidence interval, 0.84-9.97). CONCLUSIONS: Olfactory function in patients with postviral olfactory loss was significantly improved by both treatment modalities. Although the treatment response was not statistically different between the monotherapy group and the combination therapy group, the addition of G biloba showed a tendency of greater efficacy in the treatment of postviral olfactory loss.
Authors: Samuel N Helman; Jonah Adler; Aria Jafari; Sasha Bennett; Jackson R Vuncannon; Ashley C Cozart; Sarah K Wise; Merin E Kuruvilla; Joshua M Levy Journal: Allergy Asthma Proc Date: 2022-03-01 Impact factor: 2.587
Authors: Nanki Hura; Deborah X Xie; Garret W Choby; Rodney J Schlosser; Cinthia P Orlov; Stella M Seal; Nicholas R Rowan Journal: Int Forum Allergy Rhinol Date: 2020-06-25 Impact factor: 3.858
Authors: Koosha Ghazi-Moghadam; Hasan Mete Inançlı; Nazanin Bazazy; Peter K Plinkert; Thomas Efferth; Serkan Sertel Journal: Pharmaceuticals (Basel) Date: 2012-08-20